Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

131 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Soluble syndecan-1 level at diagnosis is an independent prognostic factor in multiple myeloma and the extent of fall from diagnosis to plateau predicts for overall survival.
Lovell R, Dunn JA, Begum G, Barth NJ, Plant T, Moss PA, Drayson MT, Pratt G; Working Party on Leukaemia in Adults of the National Cancer Research Institute Haematological Oncology Clinical Studies Group. Lovell R, et al. Among authors: begum g. Br J Haematol. 2005 Aug;130(4):542-8. doi: 10.1111/j.1365-2141.2005.05647.x. Br J Haematol. 2005. PMID: 16098068 Free article.
Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United kingdom Medical Research Council trials between 1980 and 2002--Medical Research Council Adult Leukaemia Working Party.
Augustson BM, Begum G, Dunn JA, Barth NJ, Davies F, Morgan G, Behrens J, Smith A, Child JA, Drayson MT. Augustson BM, et al. Among authors: begum g. J Clin Oncol. 2005 Dec 20;23(36):9219-26. doi: 10.1200/JCO.2005.03.2086. Epub 2005 Nov 7. J Clin Oncol. 2005. PMID: 16275935
Effects of paraprotein heavy and light chain types and free light chain load on survival in myeloma: an analysis of patients receiving conventional-dose chemotherapy in Medical Research Council UK multiple myeloma trials.
Drayson M, Begum G, Basu S, Makkuni S, Dunn J, Barth N, Child JA. Drayson M, et al. Among authors: begum g. Blood. 2006 Sep 15;108(6):2013-9. doi: 10.1182/blood-2006-03-008953. Epub 2006 May 25. Blood. 2006. PMID: 16728700 Free article. Clinical Trial.
Socio-economic deprivation and survival in bladder cancer.
Begum G, Dunn JA, Bryan RT, Bathers S, Wallace DM; West Midlands Urological Research Group. Begum G, et al. BJU Int. 2004 Sep;94(4):539-43. doi: 10.1111/j.1464-410X.2004.04997.x. BJU Int. 2004. PMID: 15329108
Delay and survival in bladder cancer.
Wallace DM, Bryan RT, Dunn JA, Begum G, Bathers S; West Midlands Urological Research Group. Wallace DM, et al. Among authors: begum g. BJU Int. 2002 Jun;89(9):868-78. doi: 10.1046/j.1464-410x.2002.02776.x. BJU Int. 2002. PMID: 12010230
Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia.
Tauro S, Craddock C, Peggs K, Begum G, Mahendra P, Cook G, Marsh J, Milligan D, Goldstone A, Hunter A, Khwaja A, Chopra R, Littlewood T, Peniket A, Parker A, Jackson G, Hale G, Cook M, Russell N, Mackinnon S. Tauro S, et al. Among authors: begum g. J Clin Oncol. 2005 Dec 20;23(36):9387-93. doi: 10.1200/JCO.2005.02.0057. Epub 2005 Nov 28. J Clin Oncol. 2005. PMID: 16314618 Clinical Trial.
131 results